# Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

*PRI Rank #15 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-15*

| Field | Value |
| --- | --- |
| Rank | #15 |
| 18m citations | 50 |
| Journal | Cancer Cell |
| Year | 2024 |
| DOI | 10.1016/j.ccell.2024.06.001 |
| Corresponding authors | Caicun Zhou, Tao Jiang, Zhe Zhang, Fei Li, Shengxiang Ren |
| Institution | Shanghai Pulmonary Hospital, China |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1016/j.ccell.2024.06.001](https://doi.org/10.1016/j.ccell.2024.06.001)

## Topics

HRS-4642 · KRAS G12D mutation · proteasome inhibition · combination therapy · KRAS mutation · anti-tumor efficacy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```